摘要
目的:观察人血免疫球蛋白冲击治疗难治性免疫性血小板减少性紫癜的临床疗效。方法:将符合诊断标准的220例难治性免疫性血小板减少性紫癜患者随机分为治疗组和对照组,每组各110例。组均给予泼尼松片1mg/(kg.d),2次/d,口服,服用2周,然后逐渐减量维持至停用;全反式维甲酸,每次10mg,每日3次,口服。治疗组在此基础上加用人血免疫球蛋白400mg/(kg.d)静滴,连用7d。两组均以4周为1个疗程,治疗1个疗程后观察疗效。结果:总有效率治疗组、对照组分别为94.56%、80.91%,两组相比差异统计学意义(P<0.05)。治疗后两组血清IL-2、IFN-γ、IL-4、IL-10、TGF-β1等指标相比有明显差异(P<0.05)。治疗后治疗组血小板上升情况、有效止血时间治疗组与对照组相比有明显差异(P<0.05)。结论:人血免疫球蛋白冲击治疗难治性免疫性血小板减少性紫癜疗效显著,可缩短止血时间、血小板上升时间及血小板恢复正常的时间。
AIM：To observe the impact of human serum immunoglobulin treatment of refractory immune thrombocytopenic purpura in clinical efficacy.METHODS：220 patients meet the diagnostic criteria of refractory immune thrombocytopenic purpura patients were randomly divided into treatment group and control group,110 patients in each group.Group were given prednisone tablets 1 mg/（kg·d）,2 times /d,oral,taking 2 weeks,and then gradually reducing the maintenance to be suspended;all-trans retinoic acid,each 10 mg,3 times a day,oral.On this basis,the treatment group increases the employing blood immunoglobulin 400 mg/（kg·d） infusion qd for 7 days.The two groups are 4 weeks for a course of treatment,a therapeutic effect after treatment.RESULTS：The total effective treatment group and control group were 94.56%,80.91%,statistically significant differences between two groups （P0.05）.Treatment Serum IL-2,IFN-γ,IL-4,IL-10,TGF-β1 significant differences compared to other indicators （P0.05）.Platelet counts after treatment the rates of increase,effective hemostasis time of the treatment group compared with the control group,significant difference （P0.05）.CONCLUSION：The impact of human serum immunoglobulin treatment of refractory immune thrombocytopenic purpura significant shorten the bleeding time,platelet and platelet rise-time return to normal time.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2010年第5期482-483,486,共3页
Chinese Journal of Cellular and Molecular Immunology
